• Citer

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

par Modi, Shanu;Jacot, William;Iwata, Hiroji;Park, Yeon Hee;Vidal, María Jesus M.;Li, Wei;Tsurutani, Junji;Ueno, Naoto Tada;Zaman, Khalil;Prat, Aleix;Papazisis, Konstantinos;Rugo, Hope H.S.;Yamashita, Toshinari;Harbeck, Nadia;Im, Seock–Ah –A;De Laurentiis, Michelino;Pierga, Jean Yves Ves J.Y.;Wang, Xiaojia;Gombos, Andrea ;Tokunaga, Eriko;Orbegoso Aguilar, Cecilia;Yung, Lotus;Xiao, Feng;Cheng, Yingkai;Cameron, David A
Référence Nature medicine, 31, 12, page (4205-4213)
Publication Publié, 2025-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

In DESTINY-Breast04 (NCT03734029), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician’s choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55–0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55–0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%–10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029.